Access to Information Requests Completed – December 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of December 2013

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-00536	Documents related to an infant formula company with the brand name Life. (Jan 1, 2007 to Jul 28, 2010).	Disclosed in part	14
A-2010-01264	All email correspondence about allergen labelling regulations to and from Samuel Godefroy. (Dec 1, 2010 to Feb 7, 2011).	Disclosed in part	213
A-2011-00154	Information regarding ENBREL by Immunex Corporation.	Disclosed in part	514
A-2011-01406	Information regarding Tasigna by Novartis.	Disclosed in part	322
A-2011-01538	Information regarding THRIVE GUM, NPN 80000396 and 80000402.	Disclosed in part	254
A-2012-00027	Documents pertaining to viral DNA (Deoxyribonucleic acid) contaminants of the human papilloma virus vaccines in use in Canada, Health Canada's response to any indication of such contamination and viral DNA contamination of other vaccines in use in Canada.	Disclosed in part	138
A-2012-00259	All documents related to potential safety risk with respect to the Morcellex Tissue Morcellator. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	50
A-2012-00264	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for Gynecare Prosima Pelvic Floor Repair System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	42
A-2012-00270	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for Gynecare TVT Abbrevo Continence System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	48
A-2012-00273	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for Gynecare TVT Exact Continence System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	48
A-2012-00514	Information regarding MYLAN-TELMISARTAN HCTZ, DIN 02373564, 02373572 by Mylan Pharmaceuticals ULC and TEVA-TELMISARTAN HCTZ, DIN 02330288, 02379252 by Teva Canada Limited.	Disclosed in part	491
A-2012-00559	Agenda, minutes and supporting documents for Health Canada's Healthy People and Communities Steering Committee. (Jan1, 2012 to Jul 1, 2012).	Disclosed in part	21
A-2012-00802	Information regarding CLARUS (Isotretinoin) by Mylan Pharmaceuticals ULC.	Disclosed in part	49
A-2012-00983	Information regarding PLEGISOL, DIN 00625663 by HOSPIRA HEALTHCARE CORPORATION.	Disclosed in part	183
A-2012-01459	AER for Synthroid. Report number: 000425626.	Disclosed in part	2
A-2012-01532	AERs for Diane-35. Report numbers: 000159161, 000161353, 000135800, 000159294 and 000157930.	Disclosed in part	16
A-2012-01619	AERs for Humulin. Report numbers: 000389327 and 000401731.	Disclosed in part	7
A-2012-01620	AERs for Strattera. Report numbers: 000392742, 000381559, 000383616, 000381878, 000400638, 000400816, 000407429, 000414330, 000418812 and 000429938.	Disclosed in part	20
A-2013-00020	All documents regarding the Adverse Reaction Reports for Pradex.	Disclosed in part	178
A-2013-00110	All comments received in response to the Pest Management Regulatory Agency's public consultation for the Proposed Re-evaluation Decision (PRVD) on Boric Acid and its Salts (Boron) (PRVD2012-03) posted on October 16, 2012.	Disclosed in part	877
A-2013-00198	List of problem reports received pertaining to Automated External Defibrillators. (From Jan 1, 2005 to Dec 31, 2006 and from Jan 2, 2012 to May 9, 2013).	Disclosed in part	52
A-2013-00345	Information regarding Rubbing Alcohol Compound, NPN 00167630 by RW Packaging Ltd.	Disclosed in part	44
A-2013-00419	Documents pertaining to breakfast programs as a preventative measure against child obesity. (Jan 1, 2010 to Dec 9, 2013).	Disclosed in part	296
A-2013-00502	Information regarding the medical device Circulation Maxx Ultra, License number 91704 by TV Products HK Ltd.	Disclosed in part	30
A-2013-00539	AER for Docetaxel. Report number: 000504984.	Disclosed in part	4
A-2013-00587	At the time of the repeal of licences issued under the Marihuana Medical Access Regulations on March 31, 2014, based on the actual applications received by Health Canada, as well as the licences Health Canada anticipates to issue for production of cannabis, the anticipated total annual production capacity of dried cannabis, of all anticipated Licensed Producers under the Marihuana for Medical Purposes Regulations estimated to be as of April 1, 2014.	Disclosed in part	8
A-2013-00597	AERs for Lantus. Report numbers: 000473779 and 000475205.	Disclosed in part	12
A-2013-00629	Information regarding Suboxone, DIN 02295695, 02295709 by RB Pharmaceuticals Limited.	No records exist	0
A-2013-00634	Information regarding Collagen; Cartilagen; Colla-Joint; Collagen 400 Mg; Hydrolagen; Lacogen, NPN 80039378 by Pharmetics (2011) Inc.	Disclosed in part	72
A-2013-00660	AER for Eloxatin. Report number: 000511648.	Disclosed in part	3
A-2013-00688	AERs for Avelox. Report numbers: 000504411, 000503656, 000499943, 000497113 and 000497676.	Disclosed in part	8
A-2013-00711	The number licenses to produce cannabis (marihuana) that have been issued under the Marihuana Medical Access Program to recipients within the city of Abbotsford, British Columbia	All disclosed	1
A-2013-00733	AERs for the following products/report numbers: Perindopril (000446835), Coversyl Plus (000435816, 000443532), Diamicron (000415106), Indapamide (000380218).	Disclosed in part	31
A-2013-00736	All briefing notes/memos prepared for the Minister and the Minister's office relating to prescription heroin (or otherwise known as diacetylmorphine). (Jun 1, 2013 to Sep 23, 2013).	No records exist	0
A-2013-00737	All documents regarding the Adverse Reaction for birth control pills. (Jan 1, 2009 to Sep 26, 2013).	All disclosed	1,198
A-2013-00739	List of all drugs released through the Special Access Programme. (Jan 1, 2012 to Sep 26, 2013).	All disclosed	11
A-2013-00756	Briefing notes, internal reports, Health Canada press releases and studies in regards to elderly suicide. (Jan 1, 2011 to Aug 31, 2013).	All disclosed	8
A-2013-00762	All documents in MECS for the following file: 13-107202-553, subject: Ring of Fire.	All disclosed	16
A-2013-00764	All documents in MECS for the following file: 13-107016-47. Subject: Chemicals Management Plan Timelines 2013-2016.	Disclosed in part	28
A-2013-00770	AERs: 000455368, 000463398, 000451972, 000451975, 000452321, 000463332 and 000490008.	Disclosed in part	20
A-2013-00771	Documents submitted by Prairie Plant Systems to Health Canada regarding their successful application for Marihuana for Medical Purposes Regulations.	Disclosed in part	67
A-2013-00773	The total number of valid licenses to produce Cannabis (marihuana) that have been issued by Health Canada under the Marihuana Medical Access Program to recipients within the City of Surrey, British Columbia. (Oct 31, 2011 to Aug 1, 2013).	All disclosed	1
A-2013-00788	Information regarding Hydrolyzed Collagen, NPN 80045110 by Canadian Phytopharmaceuticals Corporation.	Disclosed in part	28
A-2013-00789	Documents created or received by the deputy minister of health and/or staff, related to meetings between the Health Canada and representatives of Under Pressure Inc., a hyperbaric medicine clinic, including its co-owners. (Jan 1, 2008 to Dec 31, 2010).	No records exist	0
A-2013-00823	Information regarding Nutri King Salmon Collagen 200 Mg, NPN 80044725 by Canvors Corporation Canada Ltd.	Disclosed in part	53
A-2013-00825	List of each individual and corporation that has submitted an application to become a licensed producer under the new Marihuana for Medical Purposes Regulations.	Disclosed in part	10
A-2013-00857	Information regarding Oscillococcinum; Oscillo, DIN-HM 80014156.	Disclosed in part	16
A-2013-00867	Information regarding how Health Canada’s, Canada Health Act Division fulfills its duty to ensure criteria of the Canada Health Act are met respecting public administration of Medicare.	All disclosed	177
A-2013-00871	List of contracts of $10,000 or less in value. (Jan 1, 2013 to Oct. 29, 2013).	All disclosed	137
A-2013-00890	Documents related to a historic Kamloops-related health study, Kamloops physicians were required to collect core blood from newborn infants at Royal Inland Hospital for an extended period ending in 1999.	No records exist	0
A-2013-00895	All correspondence regarding Steven Fletcher's comments on assisted suicide. (Sep 23, 2013 to Oct 23 2013).	All disclosed	28
A-2013-00899	Documents referring to both Libby Davies and heroin. (Sep 18, 2013 to Oct 18, 2013).	All disclosed	17
A-2013-00906	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during September 2013.	All disclosed	4
A-2013-00916	All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Amendments to Rio Tinto Alcan Inc.'s British Columbia P2-00001 Multimedia Permit.	No records exist	0
A-2013-00942	AERs for Mirena. Report numbers: 000507215, 000504633, 000508319 and 000510150.	Disclosed in part	4
A-2013-00943	AERs for Magnevist. Report numbers: 000507678 and 000505483.	Disclosed in part	4
A-2013-00944	AER for Gadovist. Report number: 000511188.	Disclosed in part	4
A-2013-00946	AER for Adalat XL. Report number: 000506494.	Disclosed in part	5
A-2013-00947	AER for Yasmin. Report number: 000508692.	Disclosed in part	2
A-2013-00948	AER for Yaz. Report number: 000508740.	Disclosed in part	1
A-2013-00950	A listing of the Access to Information requests submitted to Health Canada. (Oct 1, 2013 to Oct 31, 2013).	Disclosed in part	12
A-2013-00961	AER for Biaxin. Report number: 000529184.	Disclosed in part	1
A-2013-00962	AER for Epival. Report number: 000515662.	Disclosed in part	2
A-2013-00973	AER for Adacel. Report number: 000518541.	Disclosed in part	3
A-2013-00974	AER for Ferrlecit. Report number: 000535178.	Disclosed in part	1
A-2013-00975	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during October 2013.	All disclosed	3
A-2013-00976	AER for Ferrlecit. Report number: 000531665.	Disclosed in part	1
A-2013-00977	AER for Adacel. Report number: 000537009.	Disclosed in part	1
A-2013-00978	AER for Intanza. Report number: 000518541.	Disclosed in part	3
A-2013-00980	AERs. Report numbers: 000520801, 000526131 and 000531183.	Disclosed in part	6
A-2013-00991	Electronic file of all employees, their positions and their salary classifications as of November 19, 2013.	All disclosed	122
A-2013-01000	Ministerial Agreement/Exemption granted on March 18, 2004 by the federal Minister of Health Pierre Pettigrew to the Synergy Group of Canada Inc. and Truehope Nutritional Support Ltd. allowing these companies to sell Empower Plus dietary supplement.	No records exist	0
A-2013-01003	AER. Report number: 000453103.	Disclosed in part	1
A-2013-01005	AERs for Midol. Report numbers: 000516753 and 000535428.	Disclosed in part	2
A-2013-01006	AER for Aleve. Report number: 000532366.	Disclosed in part	1
A-2013-01017	AERs for Xarelto. Report numbers: 000513479, 000514211, 000516075, 000516516, 000516541, 000517023, 000517291, 000517367, and 000520051.	Disclosed in part	11
A-2013-01018	AER for Stivarga. Report number: 000518626.	Disclosed in part	1
A-2013-01019	AERs for Mirena. Report numbers: 000513419, 000513439, 000515924 and 000517884.	Disclosed in part	8
A-2013-01020	AERs for Nexavar. Report numbers: 000517883 and 000520008.	Disclosed in part	10
A-2013-01021	AERs for Gadovist. Report numbers: 000514653, 000516265 and 000518176.	Disclosed in part	3
A-2013-01022	AERs for Diane-35. Report numbers: 000514350 and 000516118.	Disclosed in part	3
A-2013-01023	AERs for Cipro. Report numbers: 000513183, 000513257 and 000517287.	Disclosed in part	3
A-2013-01024	AERs for Avelox. Report numbers: 000512430, 000516676 and 000519746.	Disclosed in part	6
A-2013-01025	AER for Adalat XL. Report number: 000512159.	Disclosed in part	1
A-2013-01039	A list of briefing notes prepared for the minister. (Sep 1, 2013 to Nov 25, 2013).	Disclosed in part	45
A-2013-01043	AER for Eloxatin. Report number: 000526575.	Disclosed in part	1
A-2013-01045	AER for Eloxatin. Report number: 000526577.	Disclosed in part	2
A-2013-01051	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during November 2013.	All disclosed	3
A-2013-01052	AER for Eloxatin. Report number: 000531653.	Disclosed in part	1
A-2013-01053	AER for Eloxatin. Report number: 000521952.	Disclosed in part	1
A-2013-01054	AER for Eloxatin. Report number: 000535311.	Disclosed in part	1
A-2013-01055	AER for Eloxatin. Report number: 000532166.	Disclosed in part	1
A-2013-01056	AER for Eloxatin. Report number: 000529565.	Disclosed in part	1
A-2013-01063	All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Impacts of that particular aluminum smelter and potential industrial development in Kitimat on the Kitimat-Terrace airshed.	No records exist	0
A-2013-01064	All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Cost-benefit analysis of the human health or environmental impacts. Financial costs associated with the installation of scrubber technologies. Potential human health or environmental impacts.	No records exist	0
A-2013-01065	All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Experience of jurisdictions other than the Province of British Columbia that have or have not required industrial emitters of SO2 to install scrubber technologies.	No records exist	0
A-2013-01066	All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Historical emission rates, air pollutant dispersion studies, or ambient concentrations of pollutants in the Kitimat-Terrace airshed.	No records exist	0
A-2013-01067	All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Province of British Columbia's October 3, 2013 announcement of the funding of an airshed study to assess effects of existing and proposed industrial development.	No records exist	0